Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn

Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Jazz sues Avadel over Xyrem patent

16 November 2021 Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.

Big Pharma

English High Court denies Jazz units’ jurisdictional challenge

4 May 2022 Two subsidiaries of Ireland-based Jazz Pharmaceuticals have failed in their bid to challenge the jurisdiction of the English High Court in a dispute with Tokyo-headquartered Otsuka Pharmaceutical over a cannabis sativa collaboration.

Generics

Jazz Pharma’s medical cannabis unit seeks to block generic

19 January 2023 UK-based cannabidiol lab sues firms behind proposed ANDA | Feud centres on a cannabis treatment for epilepsy.

More on this story

Americas

Jazz sues Avadel over Xyrem patent

16 November 2021 Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.

Big Pharma

English High Court denies Jazz units’ jurisdictional challenge

Generics

Jazz Pharma’s medical cannabis unit seeks to block generic

19 January 2023 UK-based cannabidiol lab sues firms behind proposed ANDA | Feud centres on a cannabis treatment for epilepsy.

More on this story

Americas

Jazz sues Avadel over Xyrem patent

16 November 2021 Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.

Big Pharma

English High Court denies Jazz units’ jurisdictional challenge

Generics

Jazz Pharma’s medical cannabis unit seeks to block generic

19 January 2023 UK-based cannabidiol lab sues firms behind proposed ANDA | Feud centres on a cannabis treatment for epilepsy.